Montelukast

Administration
  • Type: Leukotriene modifier
  • Dosage Forms: granules, chewable and conventional tablets
  • Routes of Administration: PO
  • Common Trade Names: Singulair

Adult Dosing
  • Asthma (prophylaxis), allergic rhinitis: 10mg PO daily
  • Exercise-induced asthma: 10mg 2h prior to exercise max 10mg daily

Pediatric Dosing
  • 12-24mo: 4 mg (granules) PO daily
  • 2-6y: 4 mg PO daily
  • 6-15y: 5 mg PO daily
  • >15y: 10mg PO daily

>15 years: 10 mg PO daily

Special Populations

Pregnancy Rating
  • Category B

Lactation risk
  • Low risk to infant

Renal Dosing
  • Adult:
  • Pediatric:

Hepatic Dosing
  • Adult:
  • Pediatric:

Contraindications
  • Allergy to class/drug
  • Caution using chewable tablets in phenylketonuria (contain phenylalanine)

Adverse Reactions

Serious
  • Systemic eosinophilia with vasculitis consistent with Churg-Strauss syndrome
  • Neuropsychiatric events: aggressive behavior/agitation, anxiousness, hallucinations, suicidal ideation, somambulism

Common
  • Headache, dizziness
  • Abdominal pain, dyspepsia, gastroenteritis
  • Elevated LFTs
  • Viral infection, laryngitis, pharyngitis, influenza, cough, otitis, nasal congestion, bronchitis,
  • Wheezing
  • Dental pain
  • Rash, urticaria


Pharmacology
  • Half-life: 2.7-5.5h
  • Metabolism: Hepatic
  • Excretion: mostly in feces

Mechanism of Action
  • Inhibits binding of leukotriene D4 to its receptor, thus interfering with inflammatory process involved with asthma symptoms

Comments


See Also

References

Medscape

    This article is issued from Wikem. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.